Category: Alnylam suspends mid-stage extension study of hemophilia candidate fitusiran after patient death; shares down 23%

Alnylam suspends mid-stage extension study of hemophilia candidate fitusiran after patient death; shares down 23%

  1. Alnylam suspends mid-stage extension study of hemophilia candidate fitusiran after patient death; shares down 23%  Seeking Alpha
  2. Sanofi Alliance Partner Alnylam Gives Update on Fitusiran  Nasdaq
  3. Barclays Gives Alnylam Pharmaceuticals (ALNY) 22.06% Higher Target.; Japan Smaller Capitalization Fund Has 1.23 …  HuronReport
  4. Full coverage

from Business – Google News https://seekingalpha.com/news/3294061-alnylam-suspends-mid-stage-extension-study-hemophilia-candidate-fitusiran-patient-death

Advertisements